ALFA Finder| Revenue growth | FY26 growth at 10.57% YoY. |
|---|---|
| Margins | FY26 EBITDA margin improved slightly to 7.78% from 7.63%. |
| Demand visibility | Strong sugar sales; focus on value-added variants. |
| Management confidence | High; emphasizing resilience and transition to bio-energy model. |
Growth
FY26: Revenue +10.57%, EBITDA +12.79%, PAT +106.5% YoY. Q4FY26: Revenue +19.06% driven by sugar volume.
Outlook
Selling Meerganj unit (April 2026). Focusing on dual-feed ethanol and expanding potable liquor cases.
Risks
Lower Q4 revenue in Bio-Fuels (-18.79%) and Country Liquor (-2.05%) due to volume declines.
Earnings Call filed with BSE, NSE: DBOL. Summary written with AI assistance from the document.
Dhampur Bio Organics Ltd: key numbers
- Share price
- ₹146.28
- Market cap
- ₹971.1 Cr
- Revenue (annual)
- ₹2,109 Cr
- Net profit (annual)
- ₹25.18 Cr
- P/E (TTM)
- 11.6×Sector 29.1×
- Promoter holding
- 51.00%+0.22% QoQ
- FII holding
- 0.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dhampur Bio Organics Ltd
All →Dhampur Bio Organics Employee Stock Options
Dhampur Bio Organics granted 1,66,000 stock options at ₹72 exercise price under ESOS 2025. Options vest 25% annually over four years tied to performance.
Dhampur Bio Organics Board Meeting Date
Dhampur Bio Organics has scheduled a board meeting for 14 November 2026 to approve audited results and a share buyback proposal. The trading window stays closed until 16 November 2026.
Dhampur Bio Organics Management Change
Dhampur Bio Organics' VP Financial Planning and Analysis, Harmeet Singh, resigned, effective October 31, 2026. It is a senior management departure.
Dhampur Bio Organics Management Change
Dhampur Bio Organics Limited announced the cessation of Mr. Surendra Rai Kapur as Cost Auditor due to his demise, effective October 19, 2026.
Dhampur Bio Organics Partnership
Dhampur Bio Organics entered a technology licensing agreement with Planetary SA to produce Mycoprotein, with future plans for a joint venture and offtake agreement.
- Execution
- 10 years
Dhampur Bio Organics Capacity Expansion
Dhampur Bio Organics Ltd. executed a Technology Licensing Agreement with Planetary SA to produce Mycoprotein in India, introducing a new business segment and revenue stream.